SCHEMBL4966129

SCHEMBL4966129

CC(C)(C)C(C[AsH2])OC(N)=O

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.36
TSHR P16473 3/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
CYP2C9 P11712 1/20 0.36
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALOX15 P16050 1/20 0.31
CYP3A4 P08684 1/20 0.30
NFKB1 P19838 1/20 0.30
ADRA1A P35348 1/20 0.30
RAB9A P51151 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28415266 0.89 LMNA (0.38) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL28418994 0.89 LMNA (0.38) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL1829129 0.89 LMNA (0.38) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL445644 0.80 LMNA (0.38) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL20416250 0.80 LMNA (0.41) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL24623 0.78 LMNA (0.36) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL2474842 0.78 LMNA (0.36) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL3902485 0.78 LMNA (0.39) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL16330481 0.78 LMNA (0.36) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL23175147 0.77 LMNA (0.35) LMNATSHRCHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888589-A2 PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS Brystol-Myers Squibb Company (US) 2008-02-20 EP disclosed
WO-2006127287-A2 PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-30 WO disclosed